Comparative Pharmacology
Head-to-head clinical analysis: DERMOTIC versus PSORCON E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMOTIC versus PSORCON E.
DERMOTIC vs PSORCON E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dermotic (fluocinolone acetonide) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins inhibit the release of arachidonic acid, thereby suppressing the synthesis of prostaglandins and leukotrienes, leading to anti-inflammatory and immunosuppressive effects.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Each 1 mL contains 1 mg betamethasone valerate, 10 mg neomycin sulfate, 10,000 units polymyxin B sulfate. Apply 3-4 drops into affected ear(s) 2-3 times daily for 7-10 days.
Topical: Apply a thin film to affected skin areas twice daily. No systemic dosing applicable.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours. In patients with renal impairment, half-life may be prolonged; dose adjustment recommended for CrCl <30 mL/min.
Terminal elimination half-life is approximately 6-8 hours for the parent compound; active metabolites may have half-lives up to 12 hours. Clinically, this supports twice-daily dosing.
Primarily renal excretion of unchanged drug (approximately 70-80%) with the remainder metabolized and excreted via biliary/fecal routes (20-30%).
Primarily hepatic metabolism followed by renal excretion of metabolites; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for <2%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid